Old and New Molecular Targets in the Treatment of Hypertension
By:
Laisel Martinez DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida

Search for other papers by Laisel Martinez in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 24: Issue 2
Published Online:
May 2025
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2025 by the American Society of Nephrology 2025
Page Count:
10
Article Category:
Research Article
Print Publication Date:
01 May 2025
Published Online:
May 2025
  • 1.

    Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al.; Global Cardiovascular Risk Consortium: Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med 389: 1273–1285, 2023 10.1056/NEJMoa2206916 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Garofalo C, Borrelli S, Pacilio M, Minutolo R, Chiodini P, De Nicola L, et al.: Hypertension and prehypertension and prediction of development of decreased estimated GFR in the general population: A meta-analysis of cohort studies. Am J Kidney Dis 67: 89–97, 2016 10.1053/j.ajkd.2015.08.027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Doumas M, Tsioufis C, Fletcher R, Amdur R, Faselis C, Papademetriou V: Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension. J Am Heart Assoc 6: e007131, 2017 10.1161/JAHA.117.007131 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hardy ST, Jaeger BC, Foti K, Ghazi L, Wozniak G, Muntner P: Trends in blood pressure control in US adults with hypertension, 2013–2014 to 2021–2023. Am J Hypertens 38: hpae141, 2024 10.1093/ajh/hpae141 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Fryar CD, Kit B, Carroll MD, Afful J: Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021–August 2023. NCHS Data Brief 511, Hyattsville, MD, National Center for Health Statistics, 2024 10.15620/cdc/164016

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Ebinger JE, Gluckman TJ, Magraner J, Chiu ST, Rider D, Thomas C, et al.: Characterization of individuals with apparent resistant hypertension using contemporary guidelines: Insights from CV-QUIC. Hypertension 80: 1845–1855, 2023 10.1161/HYPERTENSIONAHA.123.20894 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Holmes HR, Li Q, Xu K, Kim S, Richards EM, Keeley EC, et al.: Antihypertensive medication adherence trends by sex and drug class: A pilot study. Am Heart J Plus 5: 100023, 2021 10.1016/j.ahjo.2021.100023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Huguet N, Green BB, Voss RW, Larson AE, Angier H, Miguel M, et al.: Factors associated with blood pressure control among patients in community health centers. Am J Prev Med 64: 631–641, 2023 10.1016/j.amepre.2022.11.002 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Bergland OU, Halvorsen LV, Søraas CL, Hjørnholm U, Kjær VN, Rognstad S, et al.: Detection of nonadherence to antihypertensive treatment by measurements of serum drug concentrations. Hypertension 78: 617–628, 2021 10.1161/HYPERTENSIONAHA.121.17514 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Joseph JJ, Pohlman NK, Zhao S, Kline D, Brock G, Echouffo-Tcheugui JB, et al.: Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson Heart Study. Circulation 143: 2355–2366, 2021 10.1161/CIRCULATIONAHA.120.050896 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Jędrusik P, Symonides B, Lewandowski J, Gaciong Z: The effect of antihypertensive medications on testing for primary aldosteronism. Front Pharmacol 12: 684111, 2021 10.3389/fphar.2021.684111 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Kuralay A, McDonough MC, Resch JM: Control of sodium appetite by hindbrain aldosterone-sensitive neurons. Mol Cell Endocrinol 592: 112323, 2024 10.1016/j.mce.2024.112323 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Caputo I, Bertoldi G, Driussi G, Cacciapuoti M, Calo LA: The RAAS goodfellas in cardiovascular system. J Clin Med 12: 6873, 2023 10.3390/jcm12216873 PubMed

  • 14.

    Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH: Hypertension: Renin-angiotensin-aldosterone system alterations. Circ Res 116: 960–975, 2015 10.1161/CIRCRESAHA.116.303587 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Teixeira LB, Parreiras-E-Silva LT, Bruder-Nascimento T, Duarte DA, Simões SC, Costa RM, et al.: Ang-(1-7) is an endogenous beta-arrestin-biased agonist of the AT(1) receptor with protective action in cardiac hypertrophy. Sci Rep 7: 11903, 2017 10.1038/s41598-017-12074-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Ranjit A, Khajehpour S, Aghazadeh-Habashi A: Update on angiotensin II subtype 2 receptor: Focus on peptide and nonpeptide agonists. Mol Pharmacol 99: 469–487, 2021 10.1124/molpharm.121.000236 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Messerli FH, Bangalore S, Bavishi C, Rimoldi SF: Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use? J Am Coll Cardiol 71: 1474–1482, 2018 10.1016/j.jacc.2018.01.058 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S, et al.: Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore) 95: e4071, 2016 10.1097/MD.0000000000004071 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K: Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: A systematic review and meta-analysis. J Hum Hypertens 30: 534–542, 2016 10.1038/jhh.2015.119 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Dreier R, Andersen UB, Forman JL, Sheykhzade M, Egfjord M, Jeppesen JL: Effect of increased potassium intake on adrenal cortical and cardiovascular responses to angiotensin II: A randomized crossover study. J Am Heart Assoc 10: e018716, 2021 10.1161/JAHA.120.018716 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Hoorn EJ, Gritter M, Cuevas CA, Fenton RA: Regulation of the renal NaCl cotransporter and its role in potassium homeostasis. Physiol Rev 100: 321–356, 2020 10.1152/physrev.00044.2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Preston RA, Afshartous D, Caizapanta EV, Materson BJ, Rodco R, Alonso E, et al.: Thiazide-sensitive NCC (sodium-chloride cotransporter) in human metabolic syndrome: Sodium sensitivity and potassium-induced natriuresis. Hypertension 77: 447–460, 2021 10.1161/HYPERTENSIONAHA.120.15933 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Burnier M: Should we eat more potassium to better control blood pressure in hypertension? Nephrol Dial Transplant 34: 184–193, 2019 10.1093/ndt/gfx340 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Ernst ME, Fravel MA: Thiazide and the thiazide-like diuretics: Review of hydrochlorothiazide, chlorthalidone, and indapamide. Am J Hypertens 35: 573–586, 2022 10.1093/ajh/hpac048 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Huart J, Persu A, Lengele JP, Krzesinski JM, Jouret F, Stergiou GS: Pathophysiology of the nondipping blood pressure pattern. Hypertension 80: 719–729, 2023 10.1161/HYPERTENSIONAHA.122.19996 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al.: Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 385: 2507–2519, 2021 10.1056/NEJMoa2110730 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Grimm PR, Lazo-Fernandez Y, Delpire E, Wall SM, Dorsey SG, Weinman EJ, et al.: Integrated compensatory network is activated in the absence of NCC phosphorylation. J Clin Invest 125: 2136–2150, 2015 10.1172/JCI78558 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Chun T-Y, Bankir L, Eckert GJ, Bichet DG, Saha C, Zaidi S-A, et al.: Ethnic differences in renal responses to furosemide. Hypertension 52: 241–248, 2008 10.1161/HYPERTENSIONAHA.108.109801 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Aviv A, Hollenberg NK, Weder A: Urinary potassium excretion and sodium sensitivity in blacks. Hypertension 43: 707–713, 2004 10.1161/01.HYP.0000120155.48024.6f PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Suzumoto Y, Zucaro L, Iervolino A, Capasso G: Kidney and blood pressure regulation—Latest evidence for molecular mechanisms. Clin Kidney J 16: 952–964, 2023 10.1093/ckj/sfad015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Wang B, Wen D, Li H, Wang-France J, Sansom SC: Net K+ secretion in the thick ascending limb of mice on a low-Na, high-K diet. Kidney Int 92: 864–875, 2017 10.1016/j.kint.2017.04.009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65: 1991–2002, 2004 10.1111/j.1523-1755.2004.00620.x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Balasubramanian P, Hall D, Subramanian M: Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases. Geroscience 41: 13–24, 2019 10.1007/s11357-018-0048-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Wong GW, Boyda HN, Wright JM: Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev 3: CD007451, 2016 10.1002/14651858.CD007451.pub2 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Hering L, Rahman M, Potthoff SA, Rump LC, Stegbauer J: Role of α2-adrenoceptors in hypertension: Focus on renal sympathetic neurotransmitter release, inflammation, and sodium homeostasis. Front Physiol 11: 566871, 2020 10.3389/fphys.2020.566871 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Verweij P, Danaietash P, Flamion B, Menard J, Bellet M: Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension 75: 956–965, 2020 10.1161/HYPERTENSIONAHA.119.14504 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al.; PRECISION investigators: Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400: 1927–1937, 2022 10.1016/S0140-6736(22)02034-7 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338: 784–790, 1998 10.1056/NEJM199803193381202 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al.: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 374: 1423–1431, 2009 10.1016/S0140-6736(09)61500-2 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, et al.: Divergent results using clinic and ambulatory blood pressures: Report of a darusentan-resistant hypertension trial. Hypertension 56: 824–830, 2010 10.1161/HYPERTENSIONAHA.110.156976 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Food and Drug Administration: Highlights of prescribing information: TRYVIOTM (aprocitentan) tablets, for oral use. Initial U.S. approval: 2024. Revised March 2024. Available at https://www.fda.gov/drugsatfda. Accessed April 6, 2025.

    • PubMed
    • Export Citation
  • 42.

    Shihoya W, Sano FK, Nureki O: Structural insights into endothelin receptor signalling. J Biochem 174: 317–325, 2023 10.1093/jb/mvad055 PubMed

  • 43.

    Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL Jr., et al.; Writing Committee: 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77: 772–810, 2021 10.1016/j.jacc.2020.11.022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Jackson AM, Jhund PS, Anand IS, Düngen H-D, Lam CSP, Lefkowitz MP, et al.: Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J 42: 3741–3752, 2021 10.1093/eurheartj/ehab499 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Malik AH, Aronow WS: Efficacy of sacubitril/valsartan in hypertension. Am J Ther 29: e322–e333, 2022 10.1097/MJT.0000000000000925 PubMed

  • 46.

    Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J: Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: A randomized, double-blind, multicenter study. Hypertens Res 45: 824–833, 2022 10.1038/s41440-021-00819-7 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Wang B, Wang G-H, Ding X-X, Tang H-X, Zheng J, Liu B-C, et al.: Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients. J Clin Hypertens (Greenwich) 24: 300–308, 2022 10.1111/jch.14422 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K: Twenty-four-hour blood pressure-lowering efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: A post hoc analysis of data from a randomized, double-blind multicenter study. J Am Heart Assoc 12: e027612, 2023 10.1161/JAHA.122.027612 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Zhang J, Zhang W, Yan J, Ge Q, Lu X-H, Chen S-X, et al.: Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: A phase 2 randomized, double-blind study. Hypertens Res 46: 2024–2032, 2023 10.1038/s41440-023-01326-7 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Zhang W, Zhang J, Yan J, Ge Q, Lu X-H, Chen S-X, et al.: Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension. JACC Asia 4: 697–707, 2024 10.1016/j.jacasi.2024.06.002 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S: Neprilysin inhibitors in heart failure: The science, mechanism of action, clinical studies, and unanswered questions. JACC Basic Transl Sci 8: 88–105, 2023 10.1016/j.jacbts.2022.05.010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF: Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation 104: 1856–1862, 2001 10.1161/hc4001.097191 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON-HF Investigators and Committees: Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381: 1609–1620, 2019 10.1056/NEJMoa1908655 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al.: Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138: 1505–1514, 2018 10.1161/CIRCULATIONAHA.118.034818 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Perry RJ, Shulman GI: Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem 295: 14379–14390, 2020 10.1074/jbc.REV120.008387 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Ahwin P, Martinez D: The relationship between SGLT2 and systemic blood pressure regulation. Hypertens Res 47: 2094–2103, 2024 10.1038/s41440-024-01723-6 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Zhang R, Xie Q, Lu X, Fan R, Tong N: Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr 16: 99, 2024 10.1186/s13098-024-01325-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Zhang X-L, Zhu Q-Q, Chen Y-H, Li X-L, Chen F, Huang J-A, et al.: Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc 7: e007165, 2018 10.1161/JAHA.117.007165 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al.; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019 10.1056/NEJMoa1811744 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Zhang Q, Zhou S, Liu L: Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: A new meta-analysis. Diabetol Metab Syndr 15: 118, 2023 10.1186/s13098-023-01092-z PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Liu JJ, Lee T, DeFronzo RA: Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61: 2199–2204, 2012 10.2337/db12-0052 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Wish JB, Pergola P: Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus. Mayo Clin Proc Innov Qual Outcomes 6: 536–551, 2022 10.1016/j.mayocpiqo.2022.09.002 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, et al.; BLOCK-CKD Study Group: Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study. Hypertension 78: 74–81, 2021 10.1161/HYPERTENSIONAHA.121.17073 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383: 2219–2229, 2020 10.1056/NEJMoa2025845 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al.; FIGARO-DKD Investigators: Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385: 2252–2263, 2021 10.1056/NEJMoa2110956 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, et al.; FIDELIO-DKD Investigators: Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension 79: 2685–2695, 2022 10.1161/HYPERTENSIONAHA.122.19744 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, et al.: Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens 41: 295–302, 2023 10.1097/HJH.0000000000003330 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Gadve SS, Gadve SS, Gadve S, Chavanda KS, Hanamshetti S: 878-P: Effect of finerenone on resistant hypertension in type 2 diabetes mellitus—A randomized controlled trial in Indian population. Diabetes 73: 878-P, 2024

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al.; EXCITE-HT investigators: Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: The EXCITE-HT randomized controlled study. Hypertens Res 47: 2435–2446, 2024 10.1038/s41440-024-01762-z PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al.; EXCITE-HT investigators: Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: A predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker. Hypertens Res 48: 506–518, 2024 10.1038/s41440-024-01887-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, et al.; KARDIA-1 Study Group: RNA interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial. JAMA 331: 740–749, 2024 10.1001/jama.2024.0728 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Bakris GL: Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension - KARDIA-2. Presented at the 2024 Scientific Session of the American College of Cardiology, Atlanta, GA, April 6–8, 2024

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Saxena M, Aswad A, Badariene J, Karim A, Sia YT, Stiglitz D, et al.: Subgroup results from KARDIA-2: Impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive. Eur Heart J 45: ehae666.2593, 2024 https://doi.org/10.1093/eurheartj/ehae666.2593

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Havasi A, Pagidipati N, Bakris G, Weber M, Bengus M, Daga S, et al.: KARDIA-3 study design: Zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension inadequately controlled by standard of care antihypertensives. J Hypertens 42: e120, 2024 10.1097/01.hjh.0001020524.16638.68

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al.: Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol 11: 109–119, 2023 10.1016/S2213-8587(22)00353-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, et al.; BrigHTN Investigators: Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 388: 395–405, 2023 10.1056/NEJMoa2213169 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 728 728 681
Full Text Views 140 140 112
PDF Downloads 190 190 153